Activation of Meningeal 5‐HT2B Receptors: An Early Step in the Generation of Migraine Headache?

  title={Activation of Meningeal 5‐HT2B Receptors: An Early Step in the Generation of Migraine Headache?},
  author={Karin Schmuck and Christoph Ullmer and Hans Otto Kalkman and Alphonse Probst and Hermann Lübbert},
  journal={European Journal of Neuroscience},
Several pharmaceuticals are frequently dispensed to prevent or reduce the occurrence of migraine attacks. The prophylactic effect of these drugs has been suggested to be caused through blockade of serotonin (5‐HT) receptors of type 5‐HT2B or 5‐HT2C. To elucidate which of these receptors is involved, we first used radioligand binding assays to determine the pharmacological profile of the human and rat 5‐HT2B receptor. Furthermore, the potency of drugs used in migraine prophylaxis to stimulate or… 
Putative role of 5-HT2B receptors in migraine pathophysiology
An important role of 5-HT2B receptor activation in meningeal nociception and the generation of migraine pain is suggested.
The biology of serotonin receptors: focus on migraine pathophysiology and treatment.
  • E. Hamel
  • Biology, Medicine
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • 1999
The recent availability of subtype selective 5-HT1D and 5- HT1F receptor agonists should allow a further test of the neural/vascular hypothesis and could possibly lead to antimigraine drugs with a safer cardiovascular profile.
Is the 5-HT(7) receptor involved in the pathogenesis and prophylactic treatment of migraine?
  • J. Terrón
  • Biology, Medicine
    European journal of pharmacology
  • 2002
Agonist actions of dihydroergotamine at 5‐HT2B and 5‐HT2C receptors and their possible relevance to antimigraine efficacy
Investigations aimed to determine the respective pharmacological profile of DHE and of its major metabolite 8′‐hydroxy‐DHE (8′‐OH‐D HE) at the 5‐ HT2B and 5‐HT2CRs by binding, inositol triphosphate (IP3) or cyclic GMP (cGMP) coupling studies in transfected fibroblasts.
Current and prospective pharmacological targets in relation to antimigraine action
Pharmacological targets in migraine are discussed, with special emphasis on compounds acting on 5-HT (5-HT1–7), adrenergic (α1, α2, and β), cortisol, calcitonin gene-related peptide, adenosine, glutamate, NMDA, AMPA, kainate, and metabotropic receptors, dopamine, endothelin, and female hormone (estrogen and progesterone) receptors.
5-HT7 Receptors Are Involved in Neurogenic Dural Vasodilatation in an Experimental Model of Migraine
It is demonstrated for the first time that 5-HT7 receptors are involved in neurogenic dural vasodilation evoked by electrical stimulation of dura mater and maybe of relevance in the pathophysiology and treatment of migraine.
Serotonin in migraine: theories, animal models and emerging therapies.
  • K. Johnson, L. Phebus, M. Cohen
  • Medicine, Biology
    Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques
  • 1998
A role for serotonin in migraine has been supported by changes in circulating levels of serotonin and its metabolites during the phases of a migraine attack, along with the ability of
Serotonin 5-HT2B Receptors Are Required for 3,4-Methylenedioxymethamphetamine-Induced Hyperlocomotion and 5-HT Release In Vivo and In Vitro
These findings reveal a novel regulatory component in the actions of MDMA and represent the first demonstration that 5-HT2B receptors play an important role in the brain, i.e., modulation of 5- HT release, and may serve as promising therapeutic drugs for MDMA abuse.
No evidence for functional involvement of 5-HT2B receptors in serotonin-induced vasodilatation in the human forearm.
It appears that there is no functional involvement of 5-HT2B receptors in5-HT-mediated vasodilatation in the human forearm and there was no correlation between RS-127445 concentrations and 5- HT-induced vasodolatation.


5‐Hydroxytryptamine receptor subtypes and the pharmacology of migraine
It seems likely that a single 5-HT1 receptor subtype may be found in the near future to be the final common pathway in the mechanism of action of acute antimigraine agents.
Induction of migrainelike headaches by the serotonin agonist m‐chlorophenylpiperazine
In a study of serotonin (5‐HT) function in patients with eating disorders and healthy control subjects, severe headaches with features of common migraine occurred unexpectedly in 28 of 52 subjects
Preclinical studies on the anti-migraine drug, sumatriptan.
The passage of sumatriptan and its metabolites across the blood-brain barrier appeared to be very limited, although some drug could be detected in the cerebrospinal fluid after administration of high intravenous doses.
Peripheral 5‐HT2‐like receptors. Can they be classified with the available antagonists?
Either the receptors in the different tissues are heterogeneous or the antagonists used here must be considered as unreliable probes for the classification of 5‐HT2‐like receptors, which can be interpreted in two ways.
Selective 5-HT1D alpha serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development.
The present findings suggest the importance of developing selective 5-HT1D alpha receptor agonists as a strategy to reduce the risk of myocardial infarction and possibly stroke that complicates the acute treatment of migraine headache.
Mianserin in the prophylaxis of migraine: a double‐blind study
It is concluded that mianserin is an effective migraine prophylactic in some patients because of its ability to restore to normal platelet 5‐hydroxytryptamine uptake when this is decreased in depression.
Histamine Receptors in the Isolated Human Middle Meningeal Artery. A Comparison with Cerebral and Temporal Arteries
The data considered in conjunction with the previous findings support the finding that experimental histamine-induced headache due to vasodilatation is intracranial of origin.